Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
-
Published:2024-02
Issue:
Volume:
Page:
-
ISSN:2949-7132
-
Container-title:Cancer Pathogenesis and Therapy
-
language:en
-
Short-container-title:Cancer Pathogenesis and Therapy
Author:
Zhang Changgong,
Chen Jianhua,
Wu Huijuan,
Wang Jun,
Gao Liying,
Zhao Jun,
Sun Yan,
Jia Zhongyao,
Mu Xinlin,
Bai Chunmei,
Wang Rui,
Wu Kailiang,
Liu Qiang,
Shi YuankaiORCID